000			03136nam a22003375i 4500
999			_c399166 _d399166
001			399166
003			ES-MaUEC
005			20240408094814.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230104s2023 sz | o |||| 0|eng d
020			_a9783031189036
024	7		_a10.1007/978-3-031-18903-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQR189 _b2023 EB
100	1		_aMueller, Siguna _eautor _4http://id.loc.gov/vocabulary/relators/aut _9689950
245	1	0	_aChallenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 : _bA Multidisciplinary Perspective _cby Siguna Mueller
250			_a1st ed. 2023.
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aChapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.
520			_aThis book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9140409 _aVacunas
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-18903-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b04/2024 _dz _ek _zSI